A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We believe that mental health is as important as physical health. As a global leader in neuroscience, we are delivering more treatment options to patients and healthcare providers by offering exceptional in-office treatments that produce extraordinary results. Our first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (“TMS”) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration (the “FDA”) to treat adult patients with major depressive disorder (“MDD”) who have failed to achieve satisfactory improvement from at least one prior antidepressant medication in the current MDD episode.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 130M | 75M | 71M | 65M | 55M | 49M |
| Net Income | -45M | -44M | -30M | -37M | -31M | -27M |
| EPS | $-0.83 | $-1.38 | $-1.05 | $-1.38 | $-1.22 | $-1.46 |
| Free Cash Flow | 0 | -32M | -34M | -34M | -30M | -29M |
| ROIC | -46.0% | -52.8% | -32.3% | -46.5% | -25.9% | -45.7% |
| Gross Margin | 50.4% | 72.3% | 72.5% | 76.3% | 78.9% | 76.5% |
| Debt/Equity | 2.40 | 1.99 | 1.73 | 0.63 | 0.41 | 1.36 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -38M | -35M | -31M | -35M | -28M | -22M |
| Operating Margin | -29.2% | -46.2% | -42.8% | -53.8% | -49.8% | -45.3% |
| ROE | -162.7% | -141.2% | -88.3% | -65.1% | -36.6% | -107.7% |
| Shares Outstanding | 68M | 32M | 29M | 27M | 26M | 19M |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 40M | 53M | 63M | 49M | 55M | 65M | 71M | 75M | 130M |
| Gross Margin | 76.2% | 76.4% | 75.4% | 76.5% | 78.9% | 76.3% | 72.5% | 72.3% | 50.4% |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -14M | -20M | -27M | -22M | -28M | -35M | -31M | -35M | -38M |
| Op. Margin | -33.7% | -37.6% | -43.0% | -45.3% | -49.8% | -53.8% | -42.8% | -46.2% | -29.2% |
| Net Income | N/A | -24M | -29M | -27M | -31M | -37M | -30M | -44M | -45M |
| Net Margin | N/A | -45.7% | -46.4% | -55.7% | -56.4% | -57.0% | -42.3% | -58.4% | -34.3% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||
| ROIC | N/A | -23.8% | -42.9% | -45.7% | -25.9% | -46.5% | -32.3% | -52.8% | -46.0% |
| ROE | N/A | -33.9% | -60.7% | -107.7% | -36.6% | -65.1% | -88.3% | -141.2% | -162.7% |
| ROA | N/A | -20.6% | -29.0% | -34.9% | -22.1% | -31.8% | -26.1% | -34.0% | -30.6% |
| Cash Flow | |||||||||
| Op. Cash Flow | -11M | -21M | -30M | -28M | -28M | -31M | -32M | -31M | -30M |
| Free Cash Flow | -12M | -22M | -31M | -29M | -30M | -34M | -34M | -32M | 0 |
| Owner Earnings | -12M | -23M | -35M | -34M | -37M | -41M | -41M | -39M | -38M |
| CapEx | 594K | 1.0M | 813K | 730K | 2.4M | 3.3M | 2.4M | 1.5M | 0 |
| Maint. CapEx | 596K | 882K | 1.1M | 941K | 1.1M | 1.6M | 2.0M | 2.1M | 2.1M |
| Growth CapEx | 0 | 129K | 0 | 0 | 1.3M | 1.6M | 363K | 0 | 0 |
| D&A | 596K | 882K | 1.1M | 941K | 1.1M | 1.6M | 2.0M | 2.1M | 2.1M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 496K | 1.7M | 3.4M | 4.4M | 7.9M | 8.7M | 7.3M | 5.6M | 5.6M |
| Debt Repayment | 1.0M | 0 | 0 | 39M | 0 | 91K | 1.2M | 60M | 60M |
| Balance Sheet | |||||||||
| Net Debt | 409K | -74M | -45M | -14M | -59M | -34M | -394K | 37M | 38M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 28M |
| Long-Term Debt | 30M | 30M | 20M | 35M | 35M | 23M | 59M | 55M | 55M |
| Debt/Equity | -0.15 | 0.43 | 0.65 | 1.36 | 0.41 | 0.63 | 1.73 | 1.99 | 2.40 |
| Interest Coverage | -4.8 | -5.4 | -7.3 | -4.9 | -6.9 | -8.3 | -5.6 | -4.7 | -4.7 |
| Equity | -193M | 71M | 48M | 25M | 85M | 57M | 34M | 28M | 27M |
| Total Assets | 39M | 117M | 100M | 79M | 141M | 117M | 116M | 141M | 145M |
| Total Liabilities | 232M | 46M | 52M | 53M | 56M | 60M | 82M | 109M | 114M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 38M | 38M |
| Retained Earnings | -197M | -221M | -250M | -278M | -309M | -346M | -376M | -420M | -420M |
| Working Capital | 25M | 101M | 61M | 51M | 100M | 66M | 74M | 27M | 27M |
| Current Assets | 37M | 114M | 88M | 65M | 115M | 99M | 94M | 58M | 58M |
| Current Liabilities | 12M | 14M | 28M | 14M | 16M | 33M | 20M | 31M | 31M |
| Per Share Data | |||||||||
| EPS | -86.34 | -2.69 | -1.58 | -1.46 | -1.22 | -1.38 | -1.05 | -1.38 | -0.83 |
| Owner EPS | -0.68 | -2.59 | -1.90 | -1.79 | -1.44 | -1.53 | -1.44 | -1.22 | -0.55 |
| Book Value | -10.67 | 7.93 | 2.60 | 1.36 | 3.33 | 2.12 | 1.19 | 0.87 | 0.40 |
| Cash Flow/Share | -0.62 | -2.30 | -1.66 | -1.51 | -1.09 | -1.14 | -1.11 | -0.98 | -0.62 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 18.1M | 9.0M | 18.4M | 18.8M | 25.6M | 26.9M | 28.8M | 31.7M | 68.5M |
| Valuation | |||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1.7 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 2.4 | 1.7 | 8.4 | 1.3 | 3.0 | 2.4 | 1.7 | 3.6 |
| Price/Sales | N/A | 4.5 | 3.5 | 1.5 | 5.1 | 1.5 | 1.1 | 0.9 | 0.8 |
| FCF Yield | N/A | -12.7% | -37.8% | -13.5% | -27.6% | -20.0% | -42.4% | -69.3% | N/A |
| Market Cap | N/A | 170M | 83M | 215M | 110M | 170M | 81M | 47M | 98M |
| Avg. Price | N/A | 26.24 | 12.01 | 4.06 | 10.93 | 3.65 | 2.74 | 2.18 | 1.43 |
| Year-End Price | N/A | 18.99 | 4.50 | 11.45 | 4.30 | 6.31 | 2.82 | 1.48 | 1.43 |
Neuronetics, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 75.3%.
Neuronetics, Inc. (STIM) has a 5-year average return on invested capital (ROIC) of -40.6%. This is below average and may indicate limited pricing power.
Neuronetics, Inc. (STIM) has a market capitalization of $98M. It is classified as a small-cap stock.
Neuronetics, Inc. (STIM) does not currently pay a regular dividend.
Neuronetics, Inc. (STIM) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
Neuronetics, Inc. (STIM) reported annual revenue of $75 million in its most recent fiscal year, based on SEC EDGAR filings.
Neuronetics, Inc. (STIM) has a net profit margin of -58.4%. The company is currently unprofitable.
Neuronetics, Inc. (STIM) generated $-32 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Neuronetics, Inc. (STIM) has a debt-to-equity ratio of 1.99. This indicates higher leverage, which may increase financial risk.
Neuronetics, Inc. (STIM) reported earnings per share (EPS) of $-1.38 in its most recent fiscal year.
Neuronetics, Inc. (STIM) has a return on equity (ROE) of -141.2%. A negative ROE may indicate losses or negative equity.
Neuronetics, Inc. (STIM) has a 5-year average gross margin of 75.3%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 8 years of financial data for Neuronetics, Inc. (STIM), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Neuronetics, Inc. (STIM) has a book value per share of $0.87, based on its most recent annual SEC filing.